8-K current report · filed Aug 5, 2026

Medline Inc (MDLN) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1MDLN overview

Short answer

Medline Inc (MDLN) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Earnings release covers Q2 and first six months ended June 27, 2026.

Medline Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Earnings release covers Q2 and first six months ended June 27, 2026
  • Investors should review the accompanying release for financial results and operating trends

Item EX-99.1 · Exhibit EX-99.1

  • Q2 sales $7.7B, up 11.6%, with Organic Sales growth 11.5%, confirming strong customer demand and new-account implementation
  • Q2 net income fell 58.3% to $139M, pressured by $336M Tracy fire losses and higher operating costs
  • Adjusted EBITDA rose 13.4% to $1.06B, including $243M of net IEEPA tariff refund benefits, limiting earnings quality
  • Full-year Organic Sales guidance raised to 9.0%-10.0%, while Adjusted EBITDA guidance fell to $3.3B-$3.4B
  • Six-month free cash flow $920M, with $207M capital expenditures and net leverage of 2.9 times

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Medline Inc 8-K filings

Get the next MDLN 8-K as it lands

Follow MDLN for push alerts, or ask the research agent what this filing means.